

January 30, 2024

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <u>Scrip code: 532531</u> **The National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>Scrip code: STAR</u>

Dear Madam/ Sir,

Sub: Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above, please find enclosed disclosure in prescribed format for the quarter ended December 31, 2023.

Kindly take the above submission on record.

Thanks & Regards, For **Strides Pharma Science Limited**,

Manjula Ramamurthy Company Secretary ICSI Membership No.: A30515

Encl. As above





Statement of Deviation/ Variation in utilisation of funds raised for period ended December 31, 2023

Name of Listed Entity	Strides Pharma Science Limited
Mode of Fund Raising	Preferential Issue of 2,000,000 (Two million) Equity Warrants
Date of Raising Funds	On April 26, 2022, the Company has allotted 2,000,000 (Two million) Equity Warrants to M/s. Karuna Business Solutions LLP at a price of Rs. 442/- per Warrant with a right to apply for and get allotted, within a period of 18 (Eighteen) months from the date of allotment of Warrants, in one or more tranches, 1 (one) Equity Share of face value of Rs 10/- (Rupee Ten Only) each for each Warrant.
	During September 2022, Karuna had converted 452,490 Warrants into Equity Shares.
	During October 2023, Karuna converted the remaining 1,547,510 Warrants into Equity Shares.
	As at December 31, 2023, there are no outstanding warrants.
Amount Raised	Rs. 884,000,000/-
Report for the period ending	December 31, 2023
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	None
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable



If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	Not Applicable
Objects for which funds have been raised and where there has been a deviation, in the following table	

Original Object	Modified Object, if any	Original Allocation (Rs.)	Modified allocation, if any	Funds Utilised (Rs.)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks, if any
The primary intent of the Promoter/ Promoter Group of the Company to subscribe to the Equity Warrants was to demonstrate and reiterate their continued commitment to the Company. The preferential issue was also to address the	Not Applicable	884,000,000	None	884,000,000	None	-
impact on the overall promoter group shareholding in the Company, which would reduce on account of the ongoing Promoter reclassification. The cash that shall be available with the Company pursuant to issue of Warrants, shall augment						



Company's capital resources and accelerate its growth.						
Deviation or variation could mean:						

(a) Deviation in the objects or purposes for which the funds have been raised or

- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary ICSI Membership No: A30515


